General Category > Health/Education
They Actually ADMITTED There's No Money in Curing People
bigheadfred:
Hey! Admins! I'm posting this here because I can't find the comedy category. @Cyber Liberty @mystery-ak
Error 404 (Not Found)!!1
Cyber Liberty:
Every time I scoff at something as a Conspiracy Theory, somebody comes along trying to prove me wrong. Is that a legit quote from Goldman-Sachs?
Bigun:
--- Quote from: Cyber Liberty on February 12, 2019, 05:44:20 pm ---Every time I scoff at something as a Conspiracy Theory, somebody comes along trying to prove me wrong. Is that a legit quote from Goldman-Sachs?
--- End quote ---
Same thing as hiring a government beauracrat to fix a problem!
bigheadfred:
--- Quote from: Cyber Liberty on February 12, 2019, 05:44:20 pm ---Every time I scoff at something as a Conspiracy Theory, somebody comes along trying to prove me wrong. Is that a legit quote from Goldman-Sachs?
--- End quote ---
Goldman Sachs Asks in Biotech Research Report: "Is Curing Patients a Sustainable Business Model?"
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=2ahUKEwifutmR47bgAhXpjVQKHQWPDE0QFjAAegQIABAB&url=https%3A%2F%2Fwww.cnbc.com%2F2018%2F04%2F11%2Fgoldman-asks-is-curing-patients-a-sustainable-business-model.html&usg=AOvVaw1YRipashr4-24CLRBaAzum
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
After 20 Years, This Mexican Doctor Found 100% Cure For Cervical Cancer & Human Papillomavirus
https://www.indiatimes.com/technology/news/mexican-scientist-develops-100-cure-against-hpv-which-leads-to-cervical-cancer-361867.html
It's a medical breakthrough unlike any other, one that effectively puts an end to cervical cancer among women.
After 20 painstaking years of research, Eva Ramon Gallegos, a Mexican scientist has finally developed a cure to eliminate 100 percent human papillomavirus and prevent the spread of cervical cancer among women.
Merck profits from Gardasil:
https://www.forbes.com/sites/greatspeculations/2018/10/30/keytruda-and-gardasil-will-likely-continue-to-drive-mercks-earnings-growth/
Keytruda And Gardasil Will Likely Continue To Drive Merck's Earnings Growth
Gardasil saw an impressive 38% sales growth for the nine months period ending September 2018, and we forecast the drug to garner over $3 billion in sales by the end of 2018. Gardasil is a vaccine used for prevention against HPV (human papillomavirus) virus, which has been linked to certain types of cancers, which makes it an important vaccine.
bigheadfred:
So ask yourselves. This cure for HPV could cost Merck $billions.
Merck gonna let that happen?
Navigation
[0] Message Index
[#] Next page
Go to full version